Agena Bioscience Launches New Pharmacogenetics (PGx) Panel Focused on Recommendations from Leading Societies

San Diego, CA – Agena Bioscience^®, a global provider of low-cost, high-throughput molecular testing solutions, today announced the launch of the VeriDose Core Panel v2.0 for the detection of 85 variants across 16 pharmacogenetic genes with Tier 1 and Tier 2 recommendations, all in a single, targeted panel. This makes VeriDose Core v2.0 a compelling offering for laboratories wanting a panel that provides analysis of the most relevant, society-recommended PGx content, along with simultaneous genotyping and copy number detection.

“Agena is proud to continue its focus on innovation in the PGx space, one of our core market segments” said Paul Yates, General Manager of Agena Bioscience.

“VeriDose Core v2.0 is a truly differentiated offering that was conceived out of the need to provide the market with a highly targeted solution covering the most relevant content as defined by leading societies.”

All products are For Research Use Only. Not for use in diagnostic procedures. More information is available at www.agenabio.com

About Agena Bioscience
Agena Bioscience offers the MassARRAY^® System, an open platform that enables labs to provide a highly multiplexed result in a simple workflow. With headquarters in San Diego, California, Agena markets our products in over 30 countries worldwide through direct sales offices in Germany, China and Australia, and through an extensive network of distributors. Agena Bioscience is a subsidiary of Mesa Labs, Inc.

Media Contact: Darryl Irwin
+61 (0)7 3088 1603
darryl.Irwin@agenabio.com